Leukotrienes are inflammatory chemicals the body produces during an asthma flare-up, and they’re responsible for much of what makes an attack feel so severe—tight airways, excess mucus, and swelling that makes breathing difficult. Understanding how they work explains why certain asthma medications target this pathway specifically, rather than relying on inhalers alone.
What Leukotrienes Are and Where They Come From
When something triggers an asthma reaction—things like pet dander or dust—it sets off a chain of chemical reactions in the body that produces a family of molecules called leukotrienes. These aren’t random byproducts; they’re manufactured deliberately by certain immune cells as part of the body’s inflammatory response.
Leukotrienes form when membrane phospholipids inside inflammatory cells are broken down, eventually producing arachidonic acid, which gets converted into leukotriene A4 and then into other leukotriene types. The cells primarily responsible for producing them are mast cells and eosinophils, though various immune triggers—antigens, cytokines, pollutants, and more—can spur their synthesis. Among the different leukotriene types, a subgroup called cysteinyl leukotrienes (LTC4, LTD4, and LTE4) turns out to matter most for asthma specifically.
Three Ways Leukotrienes Cause Asthma Symptoms
Bronchoconstriction. This is the most dramatic effect. Cysteinyl leukotrienes trigger airway narrowing with a potency that’s roughly 100 to 1,000 times stronger than histamine, making them among the most powerful bronchoconstricting substances known. Unlike the tightening caused by histamine, the constriction from leukotrienes also tends to last longer. Over time, this repeated tightening can contribute to structural changes in the airway itself, including thickening of smooth muscle tissue.
Inflammation and swelling. Leukotrienes draw white blood cells into the lungs, which increases swelling in the lining of the airway. Cysteinyl leukotrienes increase how permeable small blood vessels are and help recruit eosinophils—a type of white blood cell strongly associated with asthma—directly into the airways. This creates a feedback loop: more eosinophils arrive, more inflammatory chemicals get released, and the airway environment becomes increasingly reactive.
Excess mucus production. Leukotrienes act directly on the mucus-producing cells in the airway lining, prompting them to secrete more mucus than normal. They also reduce the movement of the tiny hair-like structures (cilia) that normally help clear mucus out of the lungs, making it harder for the body to get rid of the buildup it’s creating. The combination of more mucus and reduced clearance is part of why asthma attacks often involve a wet, congested feeling alongside the wheezing.
Why This Matters for Treatment
Because leukotrienes play such a central role, researchers have developed medications specifically aimed at interrupting this pathway. These antileukotriene therapies work in one of two ways: either by inhibiting the enzyme that synthesizes leukotrienes in the first place, or by blocking the receptor that leukotrienes bind to on airway cells.
One notable detail: cysteinyl leukotriene production isn’t blocked by corticosteroid therapy, which is why leukotriene-targeting medications like montelukast are often used alongside steroid inhalers rather than as a replacement for them. Leukotriene receptor antagonists have been shown to reduce bronchoconstriction in patients undergoing allergen, exercise, cold air, or aspirin-triggered asthma challenges, and they also reduce eosinophil levels in both the airway lining and the bloodstream.
What Triggers the Leukotriene Response
The chronic airway inflammation at the heart of asthma can be set off by a range of environmental and even emotional factors, including pollen, dust mites, air pollutants, certain food additives, and strong emotional states. Once triggered, the resulting inflammation contributes to long-term changes in the airway, including wall thickening and remodeling—which is part of why untreated or poorly controlled asthma tends to worsen over time rather than staying static.
Join The Discussion
Have you or someone you care for been prescribed a leukotriene receptor antagonist like montelukast as part of an asthma treatment plan? What was your experience balancing it with other medications like inhaled corticosteroids? Share your questions, experiences, or what you’ve learned about managing asthma triggers below—whether you’re newly navigating a diagnosis or have years of experience managing symptoms.
